Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/21/25 → 8/21/27 |
Funding
- Janssen Research and Development LLC: $24,750.00
25-LEUK-28-JRD (75276617AML3001): A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mu
- Qasrawi, Ayman (PI)